Sign inCreate account

Report workspace tools

NCT01288430TERMINATEDanonymous

A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors

Sponsor

Source record

Daiichi Sankyo

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

DS-2248

Indication / condition

AI-normalized

Solid Tumors

Intervention

Source record

DS-2248

Source & freshness

Source record

NCT ID

NCT01288430

Original source

ClinicalTrials.gov

Source last updated

Oct 05, 2021

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01288430

Title

A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors

Sponsor

Daiichi Sankyo

Status

TERMINATED

Phase

PHASE1

Condition raw

Solid Tumors, Non-small Cell Lung Carcinoma

Condition normalized

Solid Tumors, Non-small Cell Lung Carcinoma

Modality raw

small molecule

Modality normalized

small molecule

Target raw

DS-2248

Target normalized

DS-2248

Interventions

DS-2248

Public preview

Source record

This phase 1 clinical trial is intended to understand the safety and tolerability of a new anticancer drug in subjects with advanced solid tumors. The patients who qualify for the study will receive a once daily dose of the drug taken by mouth and will undergo several tests to measure the drug in the blood and to understand the safety, tolerability and any effect of the drug on the tumor. The antitumor effect of the drug is not known in human.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1, Open-Label, Multiple-Ascending-Dose Study of DS-2248, an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Subjects With Advanced Solid Tumors

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01288430

Status

TERMINATED

Phase

PHASE1

Sponsor

Daiichi Sankyo

Executive brief

Investment-Ready Snapshot

This phase 1 clinical trial is intended to understand the safety and tolerability of a new anticancer drug in subjects with advanced solid tumors. The patients who qualify for the study will receive a once daily dose of the drug taken by mouth and will undergo several tests to measure the drug in the blood and to understand the safety, tolerability and any effect of the drug on the tumor. The antitumor effect of the drug is not known in human.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 05, 2021
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01288430

Indication

Solid Tumors

Modality

small molecule

Target

DS-2248

Intervention

DS-2248

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.